Cargando...
Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer
In patients with refractory cancer, the effect of additional chemotherapy is very limited. Targeted agents for molecular pathways associated with cancer cell progression and survival have emerged as attractive options in several cancer types. The current pilot study assessed the efficacy and safety...
Gardado en:
| Publicado en: | Mol Clin Oncol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
D.A. Spandidos
2017
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5492817/ https://ncbi.nlm.nih.gov/pubmed/28685070 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2017.1272 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|